 |
217 Diseases |  |
228 Trials |
|
228 Trials |  |
3892 News |  |
| «12...1415161718192021222324...4950» |
- | Preclinical, Journal: Anticancer Drugs for Intra-Arterial Treatment of Colorectal Cancer Liver Metastases: In-Vitro Screening after Short Exposure Time. (Pubmed Central) - Aug 7, 2021
The aim of this study was to select the most efficient drug on a panel of colorectal cancer (CRC) cell lines (Caco-2, HCT 116, HT 29, SW 48, SW 480, SW 620) exposed for 30 min to 12 cytotoxic agents (doxorubicin, epirubicin, idarubicin, 5-FU, raltitrexed, gemcitabine, cisplatin, oxaliplatin, mitomycin C, irinotecan, streptozocin, paclitaxel) at different concentrations...Gemcitabine seemed to be the most efficient chemotherapy for SW48. Interestingly, the most commonly used cytotoxic agents in the systemic and intra-arterial treatment of colorectal liver metastasis (CRLM) (oxaliplatin, 5-FU, irinotecan) showed very limited cytotoxicity to all the cell lines.
- || Herceptin (trastuzumab) / Roche
Clinical, Journal: Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardioprotection, Italian Society of Cardiology (SIC). (Pubmed Central) - Aug 7, 2021
Cardiac function further worsens after 6 months of adjuvant trastuzumab. All LV segments are damaged, with the anterior septum and the apex showing the greatest impairments.
- mitomycin / Generic mfg., epirubicin / Generic mfg.
[VIRTUAL] The Thermal Dose during Radiofrequency-induced Hyperthermia Combined with Intravesical Chemotherapy appears to have No Significant Effect on Non-muscle Invasive Bladder Cancer Outcome (Bellini 2104) - Aug 5, 2021 - Abstract #AUA2021AUA_3409;
Our inability to identify a relationship between thermal dose and NMIBC outcome, might be attributed to access to only averaged temperature and power parameters per treatment, or to thermocouples covering only part of the inhomogeneous heated bladder wall. Occurrence of spasms has a dose limiting effect and results in lower thermal dose.
- ||| paclitaxel / Generic mfg., docetaxel / Generic mfg., epirubicin / Generic mfg.
Clinical, P3 data, Journal, Head-to-Head: Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial. (Pubmed Central) - Jul 31, 2021
TC is a safe regimen that avoids anthracycline-related side effects. This work was supported by grants from the National Natural Science Foundation of China (Grants 81672600, 81722032, 82072916, and 91959207), the 2018 Shanghai Youth Excellent Academic Leader, the Fudan ZHUOSHI Project, the Municipal Project for Developing Emerging and Frontier Technology in Shanghai Hospitals (grant SHDC12010116), the Cooperation Project of Conquering Major Diseases in the Shanghai Municipality Health System (grant 2013ZYJB0302), the Innovation Team of the Ministry of Education (grant IRT1223), and the Shanghai Key Laboratory of Breast Cancer (grant 12DZ2260100) and the National Cancer Institute (grant P30 CA16058).
- | epirubicin / Generic mfg.
Journal: A novel nuclear localization region in SIPA1 determines protein nuclear distribution and epirubicin-sensitivity of breast cancer cells. (Pubmed Central) - Jul 28, 2021
Furthermore, we found that a high expression of SIPA1 upregulated the expression of ABCB1, encoding multi-drug resistance protein MDR1, and promoted the resistance to epirubicin in breast cancer cells, while this effect was largely abolished in the cells with the expression of NLR-deleted SIPA1. This study overall, identified a nuclear localization-dependent region determining the nuclear distribution of SIPA1 and its regulation on epirubicin-sensitivity in breast cancer cells, which could be a potential drug target to facilitate the development of breast cancer chemotherapy.
- | epirubicin / Generic mfg.
Journal: Control of retention mechanisms on an octadecyl-bonded silica column using ionic liquid-based mobile phase in analysis of cytostatic drugs by liquid chromatography. (Pubmed Central) - Jul 23, 2021
The ability to change analyte retention without negatively impacting peak shape or analytical efficiency was also controlled via the tailing factor and number of theoretical plates. Based on the results, the tested ILs were classified as either effective or ineffective mobile phase additives for separation of anthracyclines and identification by LC-FL technique.
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open: NeoATCT: A Phase ? Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer (clinicaltrials.gov) - Jul 22, 2021
P2, N=32, Recruiting, Sponsor: Sichuan Provincial People's Hospital
Based on the results, the tested ILs were classified as either effective or ineffective mobile phase additives for separation of anthracyclines and identification by LC-FL technique. Not yet recruiting --> Recruiting
- epirubicin / Generic mfg.
[VIRTUAL] Complications associated with prolonged GCSF with dose-dense EC chemotherapy for early breast cancer patients () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1588;
The optimal duration of GCSF prophylaxis to reduce the FN risk with dose-dense regimens is unclear. Seven days of GCSF is associated with toxicity - a reduction to 5 days should be considered.
- paclitaxel / Generic mfg., docetaxel / Generic mfg., epirubicin / Generic mfg.
[VIRTUAL] Neoadjuvant chemotherapy (NACT) for estrogen and HER2 normal breast cancer (TNBC) in Denmark () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1582;
Surgery was reduced in more than half of the patients either by converting mastectomy to BCS or by avoiding axillary dissection. However, only 31% achieved a pCR and consequently we will in the future consider more effective chemotherapy regimens.
- AiRuiKa (camrelizumab) / Jiangsu Hengrui Medicine, Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
[VIRTUAL] Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin for early triple-negative breast cancer: A single-arm, open-label, phase II study () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1570;
Camrelizumab plus nab-paclitaxel and epirubicin resulted in higher rate of tpCR in patients with early triple-negative breast cancer and had a manageable toxicity profile. Further study is warranted to validate our findings.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Anlotinib plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: A prospective, single-arm, single-center, phase II clinical study () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1560;
Chemotherapy comprised epirubicin at 90 mg/m2 and cyclophosphamide at 600 mg/m2 followed by docetaxel at 100 mg/m2, (21 days per cycle; both total 4 cycles), which was then followed by surgery. The addition of anlotinib to neoadjuvant chemotherapy showed manageable toxicity and promising antitumor activity for patients with high-risk, early-stage TNBC.
- paclitaxel / Generic mfg., epirubicin / Generic mfg.
[VIRTUAL] Moderate physical activity (MPA) modulates immune system in breast cancer (BC) patients during preoperative chemotherapy: The NEO-RUNNER study () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1549;
TR pts showed downregulation of IL-6, IL-13 and CCL-2 during MPA. These data suggest that MPA might damp the inflammatory response to NACT.
- Ontruzant (trastuzumab biosimilar) / Merck (MSD), Samsung, AffaMed Therap, Mundipharma, Herceptin (trastuzumab) / Roche
[VIRTUAL] Five-year follow-up of the phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in patients with HER2 positive early or locally advanced breast cancer () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1546;
P=N/A
Patients were randomly assigned to receive 8 cycles of either SB3, or TRZ with concurrent neoadjuvant chemotherapy (4 cycles of docetaxel followed by 4 cycles of 5-fluorouracil/epirubicin/cyclophosphamide)... This five-year analysis of the subpopulation from the phase 3 study further supports similarity of SB3 and TRZ with comparable cardiac safety profile, and long-term efficacy.
- epirubicin / Generic mfg.
[VIRTUAL] High-risk breast cancer patients with RAD51-low tumors are characterized by good prognosis () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1538;
Biomarker analyses on treated paired tumors and on a larger cohort of pts are ongoing. will be available for the congress.
- Herceptin (trastuzumab) / Roche, TX05 (trastuzumab biosimilar) / Tanvex BioPharma
[VIRTUAL] Trial comparing the safety, efficacy and immunogenicity of trastuzumab biosimilar candidate (TX05) with originator trastuzumab in HER2+ early breast cancer () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1530;
P3
The pCR risk ratio was within the predefined equivalence margins, confirming therapeutic equivalence of TX05 and Herceptin. Secondary endpoints including ORR, safety and immunogenicity were comparable and support the conclusion of biosimilarity.
- Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Integration of gene expression and tumor-infiltrating lymphocytes (TILs) to predict pCR after neoadjuvant chemotherapy and nivolumab for patients with luminal B-like breast cancer in the phase II GIADA trial () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1522;
P2
Molecular subtype and immunity contribute to determining the sensitivity of Luminal B-like tumors to neoadjuvant sequential chemotherapy and anti-PD-1. Integrated assessment of these biomarkers should be incorporated in clinical trials of combined immuno-chemotherapy for Luminal-like breast cancer patients.
- | cisplatin / Generic mfg., epirubicin / Generic mfg.
Journal: Venous thromboembolism during preoperative chemotherapy in the CRITICS gastric cancer trial. (Pubmed Central) - Jul 22, 2021
High BMI and previous VTE were independent risk factors for VTE occurrence during preoperative chemotherapy in patients with resectable gastric cancer. VTE occurrence in the preoperative setting did not affect receipt of further treatment.
- | epirubicin / Generic mfg.
Journal: Autophagy deficiency downregulates Omethylguanine-DNA methyltransferase and increases chemosensitivity of liver cancer cells. (Pubmed Central) - Jul 22, 2021
Here, we show that autophagy-deficient liver cancer cells exhibit increased DNA damage caused by the chemotherapeutic agent epirubicin...In the absence of autophagy, the chemosensitivity of liver cancer cells was increased, but this was reversed by MGMT overexpression, indicating that autophagy mediates resistance to chemotherapy in liver cancer cells via MGMT. These findings demonstrate a direct link between autophagy, MGMT, and DNA damage repair in liver cancer cells, and show that MGMT not only regulates chemosensitivity to alkylating agents, but may also be involved in other DNA damage repair processes in autophagy-deficient cells.
- || mitomycin / Generic mfg., epirubicin / Generic mfg.
Retrospective data, Review, Journal: Efficacy of intravesical therapies on the prevention of recurrence and progression of non-muscle-invasive bladder cancer: A systematic review and network meta-analysis. (Pubmed Central) - Jul 21, 2021
IFN and MMC could be alternative therapies for BCG with slightly inferior efficacy in recurrence prevention and similar efficacy in progression prevention. However, the results of this study should be treated with caution since most of the included studies are of moderate to high risk of bias.
- | Revlimid (lenalidomide) / BMS
Journal: Repurposing of existing therapeutics to combat drug-resistant malaria. (Pubmed Central) - Jul 21, 2021
Among antibiotics, moxifloxacin exhibited better antimalarial prospective than levofloxacin, roxithromycin and erythromycin. 5-Fluorouracil, imiquimod and moxifloxacin displayed 97.64, 81.18 and 91.77 % parasite inhibition in treated animals and attained superiority in their respective groups thus could be exploited further in combination with suitable antimalarials.
- | Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Trial primary completion date, Metastases: B-IMMUNE: Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. (clinicaltrials.gov) - Jul 20, 2021
P1/2, N=57, Recruiting, Sponsor: Grand H
5-Fluorouracil, imiquimod and moxifloxacin displayed 97.64, 81.18 and 91.77 % parasite inhibition in treated animals and attained superiority in their respective groups thus could be exploited further in combination with suitable antimalarials. Trial completion date: Apr 2021 --> Jan 2022 | Trial primary completion date: Apr 2021 --> Jan 2022
- | Enrollment open: Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer (clinicaltrials.gov) - Jul 20, 2021
P4, N=110, Recruiting, Sponsor: Shengjing Hospital
Trial completion date: Apr 2021 --> Jan 2022 | Trial primary completion date: Apr 2021 --> Jan 2022 Not yet recruiting --> Recruiting
- | epirubicin / Generic mfg.
New trial: DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC (clinicaltrials.gov) - Jul 19, 2021
P=N/A, N=216, Recruiting, Sponsor: Second Affiliated Hospital of Guangzhou Medical University
- | cisplatin / Generic mfg., epirubicin / Generic mfg.
Journal: Perioperative chemotherapy in locally advanced gastric cancer in Chile: from evidence to daily practice. (Pubmed Central) - Jul 17, 2021
Five-year survival rate was 38%. We conclude that perioperative chemotherapy is feasible in public hospitals in Chile and should be offered to patients with locally advanced GC.
- || epirubicin / Generic mfg.
Biomarker, Clinical, Journal: Initial Identification of UDP-Glucose Dehydrogenase as a Prognostic Marker in Breast Cancer Patients, Which Facilitates Epirubicin Resistance and Regulates Hyaluronan Synthesis in MDA-MB-231 Cells. (Pubmed Central) - Jul 15, 2021
However, UGDH knockdown contributes to epirubicin resistance, which might be associated with increases in the expression, deposition and catabolism of hyaluronan. The results obtained allowed us to propose UGDH as a new prognostic marker in breast cancer, positively associated with development of epirubicin resistance and modulation of extracellular matrix.
- | Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Retrospective data, Journal: Retrospective comparisons of nanoparticle albumin-bound paclitaxel and docetaxel neoadjuvant regimens for breast cancer. (Pubmed Central) - Jul 11, 2021
However, grades 3-4 peripheral sensory neuropathies were more frequent in the nP group. The 2-weekly nP-based regimen might be a better choice of NST for patients with breast cancer.
- | epirubicin / Generic mfg.
Preclinical, Journal, PD(L)-1 Biomarker, IO biomarker: Combination treatment with immunogenic and anti-PD-L1 polymer-drug conjugates of advanced tumors in a transgenic MMTV-PyMT mouse model of breast cancer. (Pubmed Central) - Jul 9, 2021
Concurrent treatment of PD-L1 blocking conjugate not only abrogated the PD-L1 expression from the two disparate cellular sources, but also considerably reduced the number of immunosuppressive myeloid cells, thereby leading to a significant shrinkage of advanced tumors. Our data provide evidence that combinatory strategy of ICD-inducing and PD-L-blocking modalities could reverse immune suppression and establish a basis for the rational design of cancer immunotherapy.
- | Enrollment change, Trial withdrawal: Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC (clinicaltrials.gov) - Jul 9, 2021
P=N/A, N=0, Withdrawn, Sponsor: Hebei Medical University Fourth Hospital
Our data provide evidence that combinatory strategy of ICD-inducing and PD-L-blocking modalities could reverse immune suppression and establish a basis for the rational design of cancer immunotherapy. N=224 --> 0 | Recruiting --> Withdrawn
- | epirubicin / Generic mfg.
Journal: Comparison of two transarterial chemoembolization strategies for hepatocellular carcinoma. (Pubmed Central) - Jul 8, 2021
The proportion of grade ≥ 3 adverse events and mean hospitalisation duration for the overall TACE treatment were significantly greater in center 2 than in center 1: 56% vs. 32% (p < 0.01) and 14.2 ± 7.2 days vs. 10.3 ± 7.0 days (p < 0.01), respectively. Our results failed to show any significant survival differences between two center-related TACE strategies but showed a significantly smaller proportion of grade ≥ 3 adverse events and shorter hospitalisation for the overall treatment when the "on-demand" strategy was used.
- paclitaxel / Generic mfg., epirubicin / Generic mfg.
[VIRTUAL] An adaptive randomized neoadjuvant two arm trial in triple-negative breast cancer (TNBC) comparing a mono Atezolizumab window followed by Atezolizumab - CTX therapy with Atezolizumab - CTX therapy (neoMono) () - Jul 7, 2021 - Abstract #GSS2021GSS_47;
P2
The expected maximum number of patients to be recruited is 458. Sponsor palleos healthcare Trial information EudraCT-Number 2020-001651-40.
- | paclitaxel / Generic mfg., epirubicin / Generic mfg., gemcitabine / Generic mfg.
Journal: Interactions of Some Chemotherapeutic Agents as Epirubicin, Gemcitabine and Paclitaxel in Multicomponent Systems Based on Orange Essential Oil. (Pubmed Central) - Jul 4, 2021
Thus, two hydrophobic interactions and five π-alkyl interactions were established between EPR-LIM, the GCT-LIM connection involves four π-alkyl interactions, and the PTX-LIM bridges take place through three hydrophobic interactions and the one π-alkyl. Finally, the decomposition reaction mechanism of drugs was proposed.
- || cisplatin / Generic mfg., epirubicin / Generic mfg.
Review, Journal: Hepatic Arterial Infusion of Chemotherapy for Advanced Hepatobiliary Cancers: State of the Art. (Pubmed Central) - Jul 4, 2021
However, the efficacy of this treatment strategy remains controversial. Therefore, this review aims to summarize the current knowledge on this approach from different points of view, such as techniques, drugs pharmacology and pharmacokinetics, and clinical outcomes for advanced hepatobiliary cancers.
- | epirubicin / Generic mfg.
Journal: Translational Proteomics Analysis of Anthracycline-Induced Cardiotoxicity From Cardiac Microtissues to Human Heart Biopsies. (Pubmed Central) - Jul 3, 2021
Other proteins, such as ATP5F1B and EEF1D, showed similar responses in both the in vitro and in vivo data. This suggests that the in vitro outcomes could link to clinical phenomena in proteomic analysis.
- | epirubicin / Generic mfg., gemcitabine / Generic mfg.
New P3 trial: GENSA: Effectiveness of an Immediate Postoperative Intravesical Instillation With Either Gemcitabine or Epirubicin in Patients With Urinary Bladder Cancer (Gemcitabine Epirubicin Normal SAline) (clinicaltrials.gov) - Jun 30, 2021
P3, N=180, Not yet recruiting, Sponsor: University of Thessaly
- | Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial primary completion date: NeoSACT: The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC (clinicaltrials.gov) - Jun 30, 2021
P2, N=46, Not yet recruiting, Sponsor: Guangdong Provincial People's Hospital
This suggests that the in vitro outcomes could link to clinical phenomena in proteomic analysis. Trial primary completion date: May 2022 --> Dec 2022
- || epirubicin / Generic mfg.
Clinical, Journal: Breast tumour volume and blood flow measured by MRI after one cycle of epirubicin and cyclophosphamide-based neoadjuvant chemotherapy as predictors of pathological response. (Pubmed Central) - Jun 30, 2021
The change in breast tumour blood flow following one cycle of EC90 did not predict pathological response. Tumour volume may be a better early marker of response with such agents.
- | irinotecan / Generic mfg., epirubicin / Generic mfg.
Journal: Nrf2 Down-Regulation by Camptothecin Favors Inhibiting Invasion, Metastasis and Angiogenesis in Hepatocellular Carcinoma. (Pubmed Central) - Jun 29, 2021
In addition, H&E staining and immunofluorescence staining of VEGFR suggested angiogenesis of Huh7 and H22 tumors was reduced. In conclusion, down-regulation of Nrf2 demonstrated inhibition of invasion, metastasis, and angiogenesis of hepatoma, which may provide a potential therapy in HCC.
- | epirubicin / Generic mfg.
Journal: Identification of candidate mediators of chemoresponse in breast cancer through therapy-driven selection of somatic variants. (Pubmed Central) - Jun 24, 2021
Genomic analysis of paired pre- and post-therapy samples resulting from neoadjuvant therapy provides a powerful method for identification of mediators of response. Genes we identified should be assessed as predictive markers or targets in chemo-sensitization.
- || paclitaxel / Generic mfg., epirubicin / Generic mfg.
Clinical, Journal: Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience. (Pubmed Central) - Jun 24, 2021
Asymptomatic changes in LVEF accounted for most of the cardiotoxicity. The majority of cardiac events occurred in year one although occurrence of cardiotoxicity over time highlights the need for improved risk stratification to guide cardiac surveillance strategies.
- | epirubicin / Generic mfg.
Journal: Structural basis for stabilization of human telomeric G-quadruplex [d-(TTAGGGT)] by anticancer drug epirubicin. (Pubmed Central) - Jun 24, 2021
Binding induced thermal stabilization of G4 DNA (~36 °C), obtained from imino protons and differential scanning calorimetry, is likely to come in the way of telomerase association with telomeres. The findings pave the way for drug-designing with modifications at ring D and daunosamine sugar.
- || cisplatin / Generic mfg., docetaxel / Generic mfg., epirubicin / Generic mfg.
Clinical, Journal: Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients. (Pubmed Central) - Jun 24, 2021
The findings pave the way for drug-designing with modifications at ring D and daunosamine sugar. Our data endorse the strategy of resuming prior drugs after a chemotherapy holiday ≥ 3 months in advanced PDAC patients who achieved a durable disease control after upfront treatments.
- ||||| Vesique (APL-1202) / Asieris
Trial initiation date: Ascertain: A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in na (clinicaltrials.gov) - Jun 24, 2021
P3, N=800, Not yet recruiting, Sponsor: Jiangsu Yahong Meditech Co., Ltd aka Asieris
Our data endorse the strategy of resuming prior drugs after a chemotherapy holiday ≥ 3 months in advanced PDAC patients who achieved a durable disease control after upfront treatments. Initiation date: Mar 2021 --> Oct 2021
- || docetaxel / Generic mfg., epirubicin / Generic mfg.
Biomarker, Clinical, Clinical data, Journal: Clinical outcome and predictive factors for docetaxel and epirubicin neoadjuvant chemotherapy of locally advanced breast cancer. (Pubmed Central) - Jun 23, 2021
Docetaxel and epirubicin neoadjuvant chemotherapy showed a good response in locally advanced breast cancer. Pretreatment Ki-67 and change of Ki-67 may play a role as predictive factor for response to neoadjuvant chemotherapy.
- | epirubicin / Generic mfg.
Journal, Combination therapy, IO biomarker: Anticancer and apoptotic activities of parthenolide in combination with epirubicin in mda-mb-468 breast cancer cells. (Pubmed Central) - Jun 23, 2021
Moreover, Parthenolide treatment led to the obvious alternation of Caspase3 protein level. These results indicated that Parthenolide in combination with Epirubicin have significant cytotoxicity due to targeting the main regulators of apoptosis. Hence, according to lack of cytotoxicity of Parthenolide on normal cells that lead to reduction of drug side effects, it could be suggested as an adjuvant therapy with Epirubicin after complementary research on animal model and clinical trial.
- |||| Vesique (nitroxoline) / Asieris
Trial completion date, Trial primary completion date, Combination therapy: ACCRUE: Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients (clinicaltrials.gov) - Jun 23, 2021
P3, N=359, Active, not recruiting, Sponsor: Jiangsu Yahong Meditech Co., Ltd aka Asieris
Hence, according to lack of cytotoxicity of Parthenolide on normal cells that lead to reduction of drug side effects, it could be suggested as an adjuvant therapy with Epirubicin after complementary research on animal model and clinical trial. Trial completion date: Dec 2020 --> May 2022 | Trial primary completion date: Dec 2020 --> May 2022
- | epirubicin / Generic mfg.
Journal: RNA targeting by an anthracycline drug: Spectroscopic and insilico evaluation of Epirubicin intercation with tRNA. (Pubmed Central) - Jun 22, 2021
These spectroscopic results like the binding site of epirubicin and binding energy of epirubicin-tRNA complex were also verified by the molecular modeling results. Results of the present study provide information that aids in the development of efficient RNA targeted drugs from the existing drugs by certain chemical modification in their structure resulting in lesser side effects and better efficacy.
- || paclitaxel / Generic mfg., docetaxel / Generic mfg., epirubicin / Generic mfg.
Clinical, Journal: Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective study. (Pubmed Central) - Jun 22, 2021
Scalp cooling was generally well tolerated. These results overall suggest that the use of scalp cooling is effective in preventing alopecia in the majority of early breast cancer patients receiving neoadjuvant or adjuvant CT, especially for patients undergoing a taxane-based non-anthracycline regimen.
- | epirubicin / Generic mfg.
Journal: Computational chemogenomics drug repositioning strategy enables the discovery of Epirubicin as a new repurposed hit for P. falciparum and P. vivax. (Pubmed Central) - Jun 22, 2021
Epirubicin is originally an antitumoral agent and presents associated toxicity. However, its antiplasmodial activity not only against P. falciparum but also P. vivax in different stages of the parasite lifecycle supports the use of this drug as a scaffold for hit-to-lead optimization in malaria drug discovery.
- || Irene (pyrotinib) / Jiangsu Hengrui Medicine, Herceptin (trastuzumab) / Roche
Clinical, P2 data, Journal: Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I-III HER2-Positive Breast Cancer: A Phase II Clinical Trial. (Pubmed Central) - Jun 22, 2021
However, its antiplasmodial activity not only against P. falciparum but also P. vivax in different stages of the parasite lifecycle supports the use of this drug as a scaffold for hit-to-lead optimization in malaria drug discovery. This study showed that in HER2-positive operable or locally advanced breast cancer, the tpCR rate of P + EC-TH neoadjuvant therapy was about twice as high as that of EC-TH neoadjuvant therapy reported in other trials, with tolerable side effects.
- | epirubicin / Generic mfg.
Journal: Network integration and modelling of dynamic drug responses at multi-omics levels. (Pubmed Central) - Jun 22, 2021
These in vitro-identified modules are transferable and are evaluated with biopsies of cardiomyopathy patients. This to our knowledge most comprehensive study on anthracycline cardiotoxicity demonstrates a reproducible workflow for molecular medicine and serves as a template for detecting adverse drug responses from complex omics data.